Oral sun protection supplements have gone mainstream — but not all of them are built on the same science. When you look closely at the ingredients, doses, and clinical evidence, the differences between Heliocare and Ombré are significant.

Heliocare is one of the most recognized names in oral photoprotection, and it deserves credit for helping legitimize the category. But recognition isn't the same as efficacy. When you examine what's actually inside each capsule — particularly the dose of nicotinamide, the ingredient with the strongest clinical evidence for skin cancer prevention — a clear winner emerges.

This comparison is based entirely on publicly available product information, published clinical research, and peer-reviewed studies. We'll let the science speak.

The Critical Difference

The Nicotinamide Dose Problem

The most important ingredient in any oral sun protection supplement for skin cancer prevention is nicotinamide — a form of vitamin B3 with robust clinical evidence behind it. But the dose matters enormously. Sub-therapeutic doses don't deliver the protective effect shown in clinical trials.

Research across multiple large-scale studies — including a landmark 386-patient RCT and a 2025 analysis of 33,833 patients published in JAMA Dermatology — consistently uses 500 mg of nicotinamide twice daily as the therapeutic dose. This is the protocol that delivers a 23–54% reduction in new non-melanoma skin cancers in high-risk patients.

Heliocare 360 D Plus contains just 16 mg of niacinamide per capsule — roughly 3% of the 500 mg dose that clinical research has established as effective for skin cancer prevention. At that dose, the niacinamide in Heliocare functions primarily as a cosmetic ingredient, not a therapeutic one.

Ombré delivers 500 mg of nicotinamide per capsule — taken twice daily, matching the exact protocol used in every major clinical study on nicotinamide for skin cancer prevention.

Side-by-Side

Full Comparison

Why It Matters

You Can't Get Clinical Results From a Cosmetic Dose

Heliocare is a well-made product, and its Fernblock® (Polypodium leucotomos) technology has genuine merit. But the inclusion of 16 mg of niacinamide is a cosmetic dose — appropriate for skin brightening and barrier support, not for the skin cancer prevention that the clinical literature demands 500 mg to achieve.

This distinction matters for patients who are taking oral sun protection supplements specifically because they have a history of skin cancer, significant cumulative UV exposure, or a recommendation from their dermatologist. For those patients, the dose isn't a detail — it's the whole point.

The Verdict

Why Ombré Is the Stronger Choice

Beyond the nicotinamide dose, Ombré takes a broader formulation approach — combining four distinct mechanisms of UV protection in a single capsule:

Heliocare focuses primarily on its PLE (Fernblock®) technology, which is genuinely effective. But without therapeutic-dose nicotinamide, it leaves the most clinically significant layer of protection on the table.

Ombré was formulated by dermatologists who asked a different question: not "what ingredients can we include?" but "what does the clinical evidence actually require?" The answer shaped every ingredient and every dose.

Medical Disclaimer: This content is for educational purposes and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your dermatologist or physician before beginning any new supplement regimen. Competitor product information sourced from publicly available product pages.

Sources: [1] Chen et al., NEJM 2015 — PMC Full Text  ·  [2] Wheless et al., JAMA Dermatology 2025 — Vanderbilt Health  ·  [3] NPR Coverage  ·  [4] JAAD 2024  ·  Heliocare product data: Cantabria Labs